E.1 Medical condition or disease under investigation |
E.1.1 | Medical condition(s) being investigated |
Hormone refractory prostate cancer and skeletal metastases |
|
MedDRA Classification |
E.1.2 Medical condition or disease under investigation |
E.1.2 | Classification code | 10060862 |
|
E.1.3 | Condition being studied is a rare disease | No |
E.2 Objective of the trial |
E.2.1 | Main objective of the trial |
To compare the proportion of patients with PSA response (PSA decrease of 50% from baseline, confirmed three weeks later) of three different repeat dose regimens of Alpharadin in patients with hormone refractory prostate cancer and skeletal metastases, in order to select a dose for the Phase III programme. |
|
E.2.2 | Secondary objectives of the trial |
i) To compare the maximum percent decrease of PSA from baseline of three different repeat dose regimens of Alpharadin in order to select a dose for the Phase III programme. ii) To compare the effect on bone specific alkaline phosphatase (B-ALP) of three doses regimens of Alpharadin. iii) To examine for correlation between B-ALP and PSA. iv) To determine the effect of three different repeat dose regimens of Alpharadin on time to skeletal related events. v) To determine the effects of these three repeat dose regimens of Alpharadin on pain response, in patients with pain. vi) To determine the safety, tolerability and long-term toxicity of these three repeat dose regimens. vii) Time to death
|
|
E.2.3 | Trial contains a sub-study | Information not present in EudraCT |
E.3 | Principal inclusion criteria |
1. Histologically or cytologically confirmed adenocarcinoma of the prostate. 2. Hormone refractory with evidence of rising PSA. 3. Multifocal skeletal metastases confirmed by bone scintigraphy within the last 8 weeks 4. Performance status: ECOG 0-2 5. Life expectancy: At least 6 months 6. Laboratory test results within required parameters. 7. The patient is willing and able to comply with the protocol (including maintenance of patient diary), and agrees to return to the hospital for follow-up visits and examination 8. The patient has been fully informed about the study and has signed the informed consent form
|
|
E.4 | Principal exclusion criteria |
1. Has received an investigational drug within 4 weeks prior to the administration of radium-223, or is scheduled to receive one during the treatment and post-treatment period 2. Has received chemo-, immunotherapy, or external radiotherapy within the last 4 weeks prior to administration of study drug, or has not recovered from adverse events due to agents administered more than 4 weeks earlier 3. More than one regimen of previous cytotoxic chemotherapy 4. Has received prior hemibody external radiotherapy 5. Has a need for immediate external radiotherapy 6. Has received systemic radiotherapy with strontium-89, samarium-153, rhenium-186 or rhenium-188 for the treatment of bony metastases within the last year prior to administration of study drug 7. Has started treatment with bisphosphonates less than 3 months prior to administration of study drug. Patients are allowed to be on bisphosphonates provided patient is on a stable dose for > 12 weeks before administration of study drug. 8. Patients who are <= 4 weeks (6 weeks for bicalutamide) post withdrawal of antiandrogen therapy 9. Patients who have started on systemic steroids, within a week prior to study drug administration or who have stopped steroids within a week prior to study drug administration 10. Other currently active (relapse within the last 3 years) malignancy (except non-melanoma skin cancer) that are not prostate cancer metastases 11. Visceral metastases from prostate cancer as assessed by abdominal/pelvic CT or MRI within six weeks before administration of study drug; Lung lesions from prostate cancer as assessed by Chest Xray within 6 weeks. This requirement does not include abdominal or pelvic lymph node involvement (individual lymph node size must not exceed 1 cm in short diameter) which is acceptable. 12. Bulky loco-regional disease 13. Other serious illness or medical condition.
|
|
E.5 End points |
E.5.1 | Primary end point(s) |
Prostate Specific Antigen (PSA) response; each patient will be classified as PSA responder/non-responder according to the definition of PSA response |
|
E.6 and E.7 Scope of the trial |
E.6 | Scope of the trial |
E.6.1 | Diagnosis | Information not present in EudraCT |
E.6.2 | Prophylaxis | Information not present in EudraCT |
E.6.3 | Therapy | Yes |
E.6.4 | Safety | Yes |
E.6.5 | Efficacy | Yes |
E.6.6 | Pharmacokinetic | Information not present in EudraCT |
E.6.7 | Pharmacodynamic | Information not present in EudraCT |
E.6.8 | Bioequivalence | Information not present in EudraCT |
E.6.9 | Dose response | Yes |
E.6.10 | Pharmacogenetic | Information not present in EudraCT |
E.6.11 | Pharmacogenomic | Information not present in EudraCT |
E.6.12 | Pharmacoeconomic | Information not present in EudraCT |
E.6.13 | Others | Information not present in EudraCT |
E.7 | Trial type and phase |
E.7.1 | Human pharmacology (Phase I) | Information not present in EudraCT |
E.7.1.1 | First administration to humans | Information not present in EudraCT |
E.7.1.2 | Bioequivalence study | Information not present in EudraCT |
E.7.1.3 | Other | Information not present in EudraCT |
E.7.1.3.1 | Other trial type description | |
E.7.2 | Therapeutic exploratory (Phase II) | Yes |
E.7.3 | Therapeutic confirmatory (Phase III) | Information not present in EudraCT |
E.7.4 | Therapeutic use (Phase IV) | Information not present in EudraCT |
E.8 Design of the trial |
E.8.1 | Controlled | No |
E.8.1.1 | Randomised | Yes |
E.8.1.2 | Open | Information not present in EudraCT |
E.8.1.3 | Single blind | Information not present in EudraCT |
E.8.1.4 | Double blind | No |
E.8.1.5 | Parallel group | Information not present in EudraCT |
E.8.1.6 | Cross over | Information not present in EudraCT |
E.8.1.7 | Other | Information not present in EudraCT |
E.8.2 | Comparator of controlled trial |
E.8.2.1 | Other medicinal product(s) | No |
E.8.2.2 | Placebo | No |
E.8.2.3 | Other | No |
E.8.3 |
The trial involves single site in the Member State concerned
| No |
E.8.4 | The trial involves multiple sites in the Member State concerned | Yes |
E.8.5 | The trial involves multiple Member States | Yes |
E.8.6 Trial involving sites outside the EEA |
E.8.6.1 | Trial being conducted both within and outside the EEA | No |
E.8.6.2 | Trial being conducted completely outside of the EEA | Information not present in EudraCT |
E.8.7 | Trial has a data monitoring committee | Information not present in EudraCT |
E.8.8 |
Definition of the end of the trial and justification where it is not the last
visit of the last subject undergoing the trial
|
The end of the trial will be defined as the completion of 12-weeks follow-up after the final dose of Alpharadin to the final randomised patient, a which point the study blind will be broken. Patients will undergo continuing long-term follow-up at 9, 12, 18 and 24 months after their first injection, as is normal practice for this type of study. |
|
E.8.9 Initial estimate of the duration of the trial |
E.8.9.1 | In the Member State concerned years | 1 |
E.8.9.1 | In the Member State concerned months | 4 |
E.8.9.1 | In the Member State concerned days | |
E.8.9.2 | In all countries concerned by the trial years | 1 |
E.8.9.2 | In all countries concerned by the trial months | 4 |